sabato, 20 luglio 2024
26 Agosto 2019

EMA/FDA analysis shows high degree of alignment in marketing application decisions between EU and US

Aug 16, 2019 – EMA and the US Food and Drug Administration (FDA) are aligned in more than 90% of marketing authorisation decisions for new medicines. This is one of the findings of a joint EMA/FDA analysis comparing decisions on 107 new medicine applications at the two agencies between 2014 and 2016. The study also looked at applications for which the agencies had differing outcomes in terms of type of approval and indication. The most common reason for … (leggi tutto)